Thyroid nodules

New England Journal of Medicine

Volumn 373, Issue 24, 2015, Pages 2347-2356

  Burman, Kenneth D ^a   Wartofsky, Leonard ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THYROTROPIN;

ADULT; ANAMNESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; ECHOGRAPHY; FAMILY HISTORY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MULTICENTER STUDY; MUTATIONAL ANALYSIS; OBSERVATIONAL STUDY; PALPATION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; THYROID CANCER; THYROID NODULE; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME; ALGORITHM; BLOOD; PATHOLOGY;

ADULT; ALGORITHMS; BIOPSY, FINE-NEEDLE; FEMALE; HUMANS; PRACTICE GUIDELINES AS TOPIC; THYROID NODULE; THYROIDECTOMY; THYROTROPIN;

EID: 84949448710     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp1415786     Document Type: Review

References (50)

1. Heged L. The thyroid nodule. N Engl J Med 2004; 351: 1764-71.
2. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7: 481-93.
3. Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules: final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 1968; 69: 537-40.
4. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214.
5. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 2007; 111: 508-16.
6. Mazzaferri EL. Thyroid cancer in thyroid nodules: finding a needle in the haystack. Am J Med 1992; 93: 359-62.
7. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997; 126: 226-31.
8. Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas: prevalence by palpation and ultrasonography. Arch Intern Med 1994; 154: 1838-40.
9. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328: 553-9.
10. Sinnott B, Ron E, Schneider AB. Exposing the thyroid to radiation: a review of its current extent, risks, and implications. Endocr Rev 2010; 31: 756-73.
11. Nagataki S, Takamura N. A review of the Fukushima nuclear reactor accident: radiation effects on the thyroid and strategies for prevention. Curr Opin Endocrinol Diabetes Obes 2014; 21: 384-93.
12. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011; 96: 3390-7.
13. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2015 October 15 (Epub ahead of print).
14. Pacini F, Vorontsova T, Demidchik EP, et al. Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab 1997; 82: 3563-9.
15. Durante C, Costante G, Lucisano G, et al. The natural history of benign thyroid nodules. JAMA 2015; 313: 926-35.
16. Mester JL, Tilot AK, Rybicki LA, Frazier TW II, Eng C. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Eur J Hum Genet 2011; 19: 763-8.
17. Rowland KJ, Moley JF. Hereditary thyroid cancer syndromes and genetic testing. J Surg Oncol 2015; 111: 51-60.
18. Gara SK, Jia L, Merino MJ, et al. Germline HABP2 mutation causing familial nonmedullary thyroid cancer. N Engl J Med 2015; 373: 448-55.
19. Lupoli G, Vitale G, Caraglia M, et al. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet 1999; 353: 637-9.
20. Nagy R, Ringel MD. Genetic predisposition for nonmedullary thyroid cancer. Horm Cancer 2015; 6: 13-20.
21. Belfiore A, La Rosa GL, La Porta GA, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med 1992; 93: 363-9.
22. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10, 864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89: 163-8.
23. Hodak SP, Burman KD. The calcitonin conundrum - is it time for routine measurement of serum calcitonin in patients with thyroid nodules? J Clin Endocrinol Metab 2004; 89: 511-4.
24. Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J Endocrinol Invest 2010; 33: Suppl: 51-6.
25. Tae HJ, Lim DJ, Baek KH, et al. Diagnostic value of ultrasonography to distinguish between benign and malignant lesions in the management of thyroid nodules. Thyroid 2007; 17: 461-6.
26. Mandel SJ. Diagnostic use of ultrasonography in patients with nodular thyroid disease. Endocr Pract 2004; 10: 246-52.
27. Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005; 237: 794-800.
28. Baloch ZW, Cibas ES, Clark DP, et al. The National Cancer Institute thyroid fine needle aspiration state of the science conference: a summation. Cytojournal 2008; 5: 6.
29. Cibas ES, Ali SZ. The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol 2009; 132: 658-65.
30. Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol 2012; 56: 333-9.
31. Oertel YC, Miyahara-Felipe L, Mendoza MG, Yu K. Value of repeated fine needle aspirations of the thyroid: an analysis of over ten thousand FNAs. Thyroid 2007; 17: 1061-6.
32. Giles WH, Maclellan RA, Gawande AA, et al. False negative cytology in large thyroid nodules. Ann Surg Oncol 2015; 22: 152-7.
33. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012; 367: 705-15.
34. Eszlinger M, Krogdahl A, Münz S, et al. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules. Thyroid 2014; 24: 305-13.
35. Liu S, Gao A, Zhang B, et al. Assessment of molecular testing in fine-needle aspiration biopsy samples: an experience in a Chinese population. Exp Mol Pathol 2014; 97: 292-7.
36. Cappola AR, Mandel SJ. Molecular testing in thyroid cancer: BRAF mutation status and mortality. JAMA 2013; 309: 1529-30.
37. Kocjan G, Chandra A, Cross PA, et al. The interobserver reproducibility of thyroid fine-needle aspiration using the UK Royal College of Pathologists' classification system. Am J Clin Pathol 2011; 135: 852-9.
38. Nou E, Kwong N, Alexander LK, Cibas ES, Marqusee E, Alexander EK. Determination of the optimal time interval for repeat evaluation after a benign thyroid nodule aspiration. J Clin Endocrinol Metab 2014; 99: 510-6.
39. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998; 228: 320-30.
40. Ritter K, Elfenbein D, Schneider DF, Chen H, Sippel RS. Hypoparathyroidism after total thyroidectomy: incidence and resolution. J Surg Res 2015; 197: 348-53.
41. Cho JS, Shin SH, Song YJ, et al. Is it possible to predict hypothyroidism after thyroid lobectomy through thyrotropin, thyroglobulin, anti-thyroglobulin, and antimicrosomal antibody? J Korean Surg Soc 2011; 81: 380-6.
42. Kamran SC, Marqusee E, Kim MI, et al. Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab 2013; 98: 564-70.
43. Wharry LI, McCoy KL, Stang MT, et al. Thyroid nodules (≥4 cm): can ultrasound and cytology reliably exclude cancer? World J Surg 2014; 38: 614-21.
44. Giordano TJ, Beaudenon-Huibregtse S, Shinde R, et al. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens. Hum Pathol 2014; 45: 1339-47.
45. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013; 98: E1852-60.
46. Maia FF, Zantut-Wittmann DE. Thyroid nodule management: clinical, ultrasound and cytopathological parameters for predicting malignancy. Clinics (Sao Paulo) 2012; 67: 945-54.
47. Gharib H, Papini E, Paschke R. Thyroid nodules: a review of current guidelines, practices, and prospects. Eur J Endocrinol 2008; 159: 493-505.
48. Kwak JY, Koo H, Youk JH, et al. Value of US correlation of a thyroid nodule with initially benign cytologic results. Radiology 2010; 254: 292-300.
49. Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 2010; 34: 28-35.
50. Ito Y, Miyauchi A. Is surgery necessary for papillary thyroid microcarcinomas? Nat Rev Endocrinol 2012; 8: 9.